LeMaitre Vascular, Inc. (LMAT)

Market Cap	1.43B
Revenue (ttm)	193.48M
Net Income (ttm)	30.11M
Shares Out	22.34M
EPS (ttm)	1.34
PE Ratio	47.87
Forward PE	38.05
Dividend	$0.64 (1.00%)
Ex-Dividend Date	Mar 13, 2024

Volume	72,408
Open	63.72
Previous Close	64.23
Day's Range	63.12 - 64.67
52-Week Range	44.27 - 74.64
Beta	0.88
Analysts	Buy
Price Target	68.20 (+6.51%)
Earnings Date	Apr 30, 2024

About LMAT

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Oct 19, 2006
• Employees: 630
• Stock Exchange: NASDAQ
• Ticker Symbol: LMAT

Financial Performance

In 2023, LMAT's revenue was $193.48 million, an increase of 19.69% compared to the previous year's $161.65 million. Earnings were $30.11 million, an increase of 45.89%.

Analyst Forecast

According to 6 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price forecast is $68.2, which is an increase of 6.51% from the latest price.

Price Target

$68.2

(6.51% upside)

Analyst Consensus: Buy